Multiple Sclerosis

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the need for biomarkers that can help guide the optimal dosing for the use of anti-CD20 therapies in a precision fashion.

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the utility of real-world data, particularly when it comes to understanding subtle differences between agents from both a safety and efficacy perspective.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss emerging the practical implications of long-term data for anti-CD20 agents.

The director of the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital talked about nasal administration of foralumab that shows promise in treating patients with non-active secondary progressive MS. [WATCH TIME: 5 minutes]

Ahmed Obeidat, MD, PhD, and Riley Bove, MD, review strategies for how to make drug classes and the risks-benefits profiles of individual agents accessible to patients.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the factors to consider when determining whether patients are candidates for anti-CD20 therapies.

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the challenges with access to care in multiple sclerosis, particularly for marginalized communities, despite significant progress made in the field over the past decades. [WATCH TIME: 4 minutes]

To date, treatment with foralumab has shown promising results in stabilizing or improving clinical measures without serious adverse effects among patients with non-active secondary progressive multiple sclerosis.

The award ceremony is supported by EMD Serono and Viatris and will take place on Thursday, May 30, 2024, at the Nashville Music City Center in Nashville, Tennessee, during the 2024 CMSC Annual Meeting.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, review the benefits of exercise and physical activity in patients with MS. They also discuss strategies for talking to patients about the positive effects of lifestyle changes.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the importance of monitoring bladder dysfunction symptoms in MS care.

The associate professor of neurology at Harvard Medical School discussed findings from a study investigating nasal foralumab in patients with non-active secondary progressive multiple sclerosis. [WATCH TIME: 5 minutes]

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, review strategies for optimizing treatment of women with MS who are pregnant while minimizing risks. They also talk about evolving approaches to managing women who are breastfeeding.

Ahmed Obeidat, MD, PhD, Erin Longbrake, MD, PhD, Stephen Krieger, MD, and Riley Bove, MD, discuss differences in immunologic phenotypes across racial boundaries. They also discuss data showing that, despite these differences, response to high-efficacy agents appears to be consistent regardless of race.

Ofatumumab showed a consistent and long-term reduction in relapse rates and MRI lesion activity in patients with recently diagnosed, treatment-naïve relapsing multiple sclerosis.

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the unevenly distributed progress in multiple sclerosis care, impacting minority populations who often face worse disease outcomes. [WATCH TIME: 6 minutes]

The neurology resident at Massachusetts General Brigham talked about assessing the safety of cancer treatments in patients with multiple sclerosis using checkpoint inhibitors. [WATCH TIME: 6 minutes]

The associate professor of neurology at University of California, San Francisco talked about findings from an analysis that assessed the safety of ocrelizumab when administered close to pregnancy. [WATCH TIME: 5 minutes]

The executive vice president of research at National MS Society talked about the Dystel Prize which is presented at AAN to a recognized individual who promotes further advancements in understanding and treating MS. [WATCH TIME: 3 minutes]

Ahmed Obeidat, MD, PhD, Erin Longbrake, MD, PhD, Stephen Krieger, MD, and Riley Bove, MD, discuss strategies for personalizing decisions and mitigating risks when stopping medication.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the definition of high-efficacy therapy and its place in MS care.

The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]

The professor of materials science and engineering at Cornell University and chief executive officer at Artificial Axon Labs talked about the development of artificial axons through 3D printing. [WATCH TIME: 6 minutes]